
BLTE Stock Forecast & Price Target
BLTE Analyst Ratings
Bulls say
Belite Bio is a promising clinical stage biopharmaceutical company with an innovative drug pipeline targeting degenerative retinal diseases and metabolic diseases with unmet medical needs. Its lead candidate, tinlarebant, has shown promising results and has been granted multiple designations by the US FDA. With a potential NDA submission in 2Q26 and a potential commercial launch in 1Q27, combined with the company's plans for a sales team and broad label for patients above 12 years of age, we believe Belite Bio has great potential and we reiterate our Buy rating.
Bears say
Belite Bio is well-funded to complete the regulatory process, with a net loss of $77.6M and cash of $772.6M at the end of FY2025. However, with ongoing trials and limited product candidates, the company may struggle to generate significant revenue and reach profitability in the near future. The potential success of tinlarebant and LBS-009 will heavily impact the company's future performance and should be closely monitored.
This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
BLTE Analyst Forecast & Price Prediction
Start investing in BLTE
Order type
Buy in
Order amount
Est. shares
0 shares